The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.
Regina Dalmau González-GallarzaAlberto Cordero-FortLuís MasanaEmilio RuizAntoni Sicras-MainarJosé Ramón González JuanateyPublished in: European heart journal open (2024)
In IHD, the CNIC-polypill exemplifies a guideline-recommended secondary prevention treatment linked to better outcomes and cost saving compared with other therapeutic options.